18:38 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Spinal cord injury (SCI) Rat studies suggest human embryonic stem cell (hESC)-derived spinal cord neural stem cells (NSCs) could help treat SCI. hESCs were cultured with fibroblast growth factors and inhibitors of bone morphogenic...
15:47 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD)...
17:56 , May 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Rett syndrome Patient sample and mouse studies suggest inhibiting GSK3B could help treat Rett syndrome. In postmortem cerebellum tissue samples from Rett syndrome patients, levels of GSK3B were higher than in samples from unaffected...
21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing...
13:32 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Fate reports Phase I data for Fate-NK100 in ovarian cancer

Fate Therapeutics Inc. (NASDAQ:FATE) reported data from two evaluable patients with ovarian cancer in the Phase I APOLLO trial showing that Fate-NK100 led to stable disease with evidence of tumor reduction at day 28 in...
22:36 , Apr 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018...
17:46 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

AMO Pharma reports Phase II data for myotonic dystrophy candidate

AMO Pharma Ltd. (Surrey, U.K.) reported data from a Phase II trial in 16 patients ages 13-34 with congenital or childhood-onset myotonic dystrophy type 1 (DM1) showing that tideglusib (AMO-02) was generally well tolerated with...
23:10 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; autoimmune disease

INDICATION: Solid tumors; Crohn’s disease; inflammatory bowel disease (IBD)...
17:35 , Mar 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML)...
23:11 , Mar 7, 2018 |  BC Extra  |  Preclinical News

Selectively inhibiting GSK3's double genes for AML

Researchers at the Broad Institute of MIT and Harvard and colleagues found a way to design highly selective glycogen synthase kinase 3 inhibitors that target one of two forms of the gene. The approach could...